Recent House Activities; Eye on the States; Nonproprietary Naming of Biological Products; Interchangeability with Reference Product; Drug Price Transparency in Medicare & Medicaid; PA and UM Concepts in Managed Care Pharmacy
August 2019 News & Views: Read articles about AMCP’s new website, board of directors meeting, AMCP Diplomat spotlight, the Nexus 2019 General Session keynote speaker, and much more.
Press Release: AMCP comments in joint statement on the Administration’s latest initiative to modernize substance use disorder (SUD) treatment privacy law and enhance coordinated care and safety.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to its proposed rule, “Medicare Program; Secure Electronic Prior Authorization for Medicare Part D [CMS-4819-P]” published in the Federal Register on June 19, 2019.
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to the notice titled “Advance Summary of Methodological Changes for Calendar Year (CY) 2020 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2020 Call Letter [CMS-2018-0154]” released on January 30, 2019.
A retrospective claims data analysis published in JMCP found that patients with metastatic melanoma treated with PD-1 had substantially lower costs than patients treated with other first line agents.
This JMCP article describes how discoveries made through a validation process improved the accuracy and transparency of a previously published budget impact analysis model that overestimated utilization following a formulary change.